U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 3S.2Sb
Molecular Weight 339.715
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANTIMONY TRISULFIDE

SMILES

[S--].[S--].[S--].[Sb+3].[Sb+3]

InChI

InChIKey=NVWBARWTDVQPJD-UHFFFAOYSA-N
InChI=1S/3S.2Sb/q3*-2;2*+3

HIDE SMILES / InChI
Molecular Formula HS
Molecular Weight 33.073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula Sb
Molecular Weight 121.76
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7ef48d40-6d63-440b-a73c-46d89f425936

Stibophen (Fuadin), an organic trivalent antimony compound, has been used for many years in the treatment of schistosomiasis. Stibophen is used as treatment of schistosomiasis by intramuscular injection. Stibophen is known to act by selectively inhibiting worm PFK.

Originator

Approval Year

1921
1467
Targets

Targets

Primary TargetPharmacologyConditionPotency
ATP-dependent 6-phosphofructokinase
21
Target ID: Q27778
Gene ID: NA
Gene Symbol: PFK
Target Organism: Schistosoma mansoni (Blood fluke)
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Approved
8429
Fuadin

Approved Use

Schistosomiasis
PubMed

PubMed

TitleDatePubMed
Evaluation of fuadin therapy in schistosomiasis japonica.
1951 Apr
Laboratory studies on the joint effects of certain tris (p-aminophenyl) carbonium salts and antimonials as antischistosomal drugs.
1965
Current chemotherapy of schistosomiasis japonica in the Philippines.
1976 Jun
[Substantiation of maximum permissible levels of antimony trioxide and pentasulide in the atmospheric air of inhabitated places].
1989 Apr
Purification, kinetics and inhibition by antimonials of recombinant phosphofructokinase from Schistosoma mansoni.
1996 Oct 30
Antimony impairs nucleotide excision repair: XPA and XPE as potential molecular targets.
2010 Jul 19
Investigation on the pharmacological profile of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives and their antimony(III) and bismuth(III) complexes.
2012 Jul
Patents

Patents

03976788
20
04062962
20
04197262
20
04562009
22
04596784
20
05025031
25
05463088
20
05656573
25
05776425
20
07713950
20
07737233
22
08268997
20
08354532
21
20080146527
20
20090076227
20
20090124802
20
7361689
20
7615300
20
US3085943
20
US3965016
20
US5232441
21

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:32:37 GMT 2023
Edited
by admin
on Fri Dec 15 15:32:37 GMT 2023
Record UNII
F79059A38U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ANTIMONY TRISULFIDE
MART.   MI  
Common Name English
ANTIMONIUM CRUDUM
HPUS  
Common Name English
ANTIMONY TRISULFIDE COLLOID [HSDB]
Common Name English
Antimony trisulfide colloid [WHO-DD]
Common Name English
ANTIMONY TRISULPHIDE COLLOID
Common Name English
ANTIMONY TRISULFIDE [IARC]
Common Name English
ANTIMONY TRISULFIDE COLLOID
HSDB   USAN   WHO-DD  
USAN  
Official Name English
ANTIMONY TRISULPHIDE
Common Name English
ANTIMONY TRISULFIDE COLLOID [USAN]
Common Name English
ANTIMONY SULPHIDE (SB2S3)
Common Name English
ANTIMONIUM CRUDUM [HPUS]
Common Name English
Antimony sulfide (Sb2S3)
Common Name English
ANTIMONY TRISULFIDE [MI]
Common Name English
ANTIMONY TRISULFIDE [MART.]
Common Name English
Code System Code Type Description
CAS
1345-04-6
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
SMS_ID
100000151577
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
EPA CompTox
DTXSID6030732
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
RXCUI
1316091
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY RxNorm
EVMPD
SUB51532
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
HSDB
1604
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
DAILYMED
F79059A38U
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
FDA UNII
F79059A38U
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
PUBCHEM
9862749
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
ECHA (EC/EINECS)
215-713-4
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
MESH
C064234
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
EVMPD
SUB125764
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
WIKIPEDIA
Antimony trisulfide
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
NCI_THESAURUS
C45678
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
CONCEPT Industrial Aid
NCI_THESAURUS
C142927
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY
MERCK INDEX
m1971
Created by admin on Fri Dec 15 15:32:37 GMT 2023 , Edited by admin on Fri Dec 15 15:32:37 GMT 2023
PRIMARY Merck Index
Related Record Type Details
Structure of HYDROGEN SULFIDE
PARENT -> SALT/SOLVATE
Structure of ANTIMONY CATION (3+)
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of ANTIMONY TRISULFIDE
ACTIVE MOIETY
Structure of ANTIMONY CATION (3+)
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966